| 2024-03-27 | +1.48 % |
|
| 2024-03-22 | -0.31 % |
- The article discusses Charles River Laboratories International, Inc. (CRL) stock, which was down by -0.31% last night, with analysts giving it an average "Moderate Buy" rating and a 1-year price target of $249.64, citing various analyst ratings and recent insider selling. The stock likely went down due to a combination of factors such as profit-taking by insiders and possibly market sentiment influenced by analyst ratings.
- The article discusses institutional investors' recent adjustments to their holdings in Charles River Laboratories International, with Baker Tilly Wealth Management LLC reducing its stake in the company, and other firms like Wetherby Asset Management Inc. and Raymond James Trust N.A. increasing their holdings, leading to -0.31% downward movement in CRL stock. This decrease in stock value could be influenced by various factors such as changes in institutional investor positions, quarterly earnings data, analyst ratings, and insider selling activities.
|
| 2024-03-21 | +1.96 % |
|
| 2024-03-14 | -0.26 % |
|
| 2024-02-29 | -0.99 % |
- The article discusses Elanco Animal Health Incorporated's response to Ancora Holdings Group, LLC's submission of four nominees to the Company's Board of Directors. The company highlights its operational progress, growth, and engagement with shareholders, amidst Ancora's demands for board changes. Charles River Laboratories (CRL) stock went down by -0.99% last night due to external factors, such as overall market conditions, the company's performance outlook, and potential investor sentiments.
- Charles River Laboratories (CRL) stock was down -0.99% last night as Wheeler Bio, Inc. and Charles River Laboratories International, Inc. announced a strategic agreement to offer Wheeler Bio's Portable CMC® platform, aiming to accelerate the transition from pre-clinical stages to human clinical trials, potentially causing stock decline due to market reaction or other factors impacting the company's financial performance.
|
| 2024-02-28 | +1.49 % |
- Charles River Laboratories (CRL) stock went up by 1.49% last night, following Northern Trust Corp's increase in its position by 5.1% during the third quarter, with other large investors also adding to their stakes in the company, as analysts have given favorable ratings and price targets, while key company executives made significant stock sales recently.
- The article discusses Natixis Advisors L.P. increasing its position in Charles River Laboratories International stock by 17.4% during the third quarter, with various other institutional investors also buying shares, contributing to an increase in the stock price by 1.49% last night. The rise in the stock may be attributed to increased investor confidence and positive quarterly earnings results reported by the company.
- The article discusses the recent increase in Charles River Laboratories International, Inc. (CRL) stock by 1.49%, attributed to Natixis Advisors L.P. increasing its stake in the company, along with other large investors modifying their holdings, and positive quarterly earnings results exceeding analysts' estimates.
|
| 2024-02-27 | +1.36 % |
|
| 2024-02-26 | +0.75 % |
|
| 2024-02-23 | +0.33 % |
|
| 2024-02-21 | +0.9 % |
|
| 2024-02-20 | -2.46 % |
- Summary: Charles River Laboratories International, Inc. (NYSE:CRL) stock was down 2.46% last night as UBS Group AG decreased its position, selling shares during the quarter, and several other hedge funds modified their holdings, leading to a drop in the stock value.
Reason for stock decline: The stock of Charles River Laboratories International, Inc. (CRL) went down due to UBS Group AG lowering its position in the company, coupled with other hedge funds also adjusting their holdings, leading to a decrease in the stock's value.
- The article discusses Charles River Laboratories International, Inc. entering into an agreement with Pluristyx Inc. to enhance its research tools supporting therapeutic development by adding ES cells and iPSCs, which contributed to the stock going down, potentially due to market reactions or other external factors impacting investor sentiment towards the company.
- The article discusses Qtron Investments LLC acquiring a new position in Charles River Laboratories International and various hedge funds and institutional investors buying and selling shares of the company, ultimately leading to the stock being down -2.46% last night. The stock may have decreased due to general market conditions, investor sentiment, profit-taking, or a combination of these factors.
|
| 2024-02-15 | +0.11 % |
|
| 2024-02-14 | +11.3 % |
|
| 2024-02-09 | +1.58 % |
|
| 2024-02-07 | -0.87 % |
|
| 2024-02-06 | +1.34 % |
|
| 2024-02-05 | -0.27 % |
|
| 2024-01-29 | +1.94 % |
|
| 2024-01-26 | +3.4 % |
|
| 2024-01-25 | -0.04 % |
|
| 2024-01-24 | -0.44 % |
|
| 2024-01-23 | -0.82 % |
|
| 2024-01-22 | +1.79 % |
|
| 2024-01-16 | -2.39 % |
|
| 2024-01-08 | +1.36 % |
|
| 2023-12-18 | -1.18 % |
|
| 2023-12-12 | +2.05 % |
|
| 2023-11-28 | +0.27 % |
|
| 2023-11-27 | -1.12 % |
|
| 2023-11-16 | +1.06 % |
|
| 2023-11-10 | +1.49 % |
|
| 2023-11-09 | -3.69 % |
|
| 2023-11-08 | -3.74 % |
|
| 2023-11-03 | +4.12 % |
|
| 2023-10-31 | +2.33 % |
|
| 2023-10-24 | +1.32 % |
|
| 2023-10-19 | +1.21 % |
|
| 2023-10-16 | +0.9 % |
|
| 2023-10-11 | +0.74 % |
|
| 2023-10-09 | -0.2 % |
|